Dr. Gardner has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from the American College of Rheumatology and the American College of Physicians.
Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra
Article first published online: 26 JUL 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 8, pages 1381–1384, August 2013
How to Cite
Ghosh, P., Cho, M., Rawat, G., Simkin, P. A. and Gardner, G. C. (2013), Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra. Arthritis Care Res, 65: 1381–1384. doi: 10.1002/acr.21989
- Issue published online: 26 JUL 2013
- Article first published online: 26 JUL 2013
- Accepted manuscript online: 6 MAY 2013 01:33PM EST
- Manuscript Accepted: 13 FEB 2013
- Manuscript Received: 29 OCT 2012
- NIH T-32 Training Grant
- American College of Rheumatology Fellowship Training Award
- Arthritis Foundation Training Grant
To report our experience with the efficacy and safety of anakinra for acute gouty arthritis in medically complex hospitalized patients.
We reviewed the hospital charts of 26 patients treated with anakinra for crystal-induced arthritis since 2007. Demographics, comorbid conditions, reason for anakinra use, response to treatment, and any adverse outcomes were recorded.
Twenty-six patients received 40 courses of anakinra therapy. In 67% of patients, pain improved significantly within 24 hours, and complete resolution of signs and symptoms of gout occurred by day 5 in 72.5% of patients. Seven patients received multiple courses with no decrement in response with repeated treatments. Anakinra was well tolerated and no adverse outcomes were attributed to the medication. Only 1 patient appeared to be refractory to this form of interleukin-1 inhibition.
Anakinra is an effective and safe alternative treatment for acute gouty arthritis in medically complex hospitalized patients who fail or cannot undergo more conventional therapy.